Amplicore Inc., a Cincinnati, OH-based early-stage biopharmaceutical company, closed its $4m seed round of funding.
The round was led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital.
Led by Dr. Chia-Ying (James) Lin, Founder, President, and CEO, Amplicore is a biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases.
The company intends to use the funds to complete the preclinical development of its two leading products, AM3101 and AM1101, and position itself for the next round of financing. Amplicore is also leveraging a study on the healing of acute meniscal tear after surgical repair, supported by a grant from the US Department of Defense (DoD). The company is also developing AM1101 as a treatment for osteoarthritis (OA) designed to reduce joint OA pain, inhibit cartilage degradation, and promote tissue regeneration of the aberrant cartilage associated with the disease.